By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    benefits of using protein powder to build muscles
    Protein Powder for Muscle Mass: Everything You Need to Know
    December 12, 2021
    changes brought on by blockchain in healthcare
    Technology In The Healthcare Industry
    March 28, 2022
    What Does Core Body Temperature Say About Health?
    August 17, 2022
    Latest News
    Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
    May 16, 2025
    Learn how to Renew your Medical Card in West Virginia
    May 16, 2025
    Choosing the Right Supplement Manufacturer for Your Brand
    May 1, 2025
    Engineering Temporary Hospitals for Extreme Weather
    April 24, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    FDA Approves Diabetes Pill
    May 2, 2011
    Patient Gets Drunk on Hand Sanitizer
    June 20, 2011
    Cultivating Health Improvement
    July 20, 2011
    Latest News
    Building Smarter Care Teams: Aligning Roles, Structure, and Clinical Expertise
    May 18, 2025
    The Critical Role of Healthcare in Personal Injury Recovery: A Comprehensive Guide for Victims
    May 14, 2025
    The Backbone of Successful Trials: Clinical Data Management
    April 28, 2025
    Advancing Your Healthcare Career through Education and Specialization
    April 16, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: OXiGENE Releases Promising Phase Two Data For Lung Cancer Drug
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > OXiGENE Releases Promising Phase Two Data For Lung Cancer Drug
Technology

OXiGENE Releases Promising Phase Two Data For Lung Cancer Drug

HerinaAyot
Last updated: June 6, 2011 7:24 pm
HerinaAyot
Share
3 Min Read
SHARE

OXiGENE (NASDAQ:OXGN) shares rose in pre-market trading on Monday as it announced on the weekend that follow-up results from a phase two study of Zybrestat showed that patients with non-small cell lung cancer had better response and survival rates.

The controlled, randomized trial, called Falcon, tested Zybrestat in combination with three other treatments, compared to the control arm of the study.

OXiGENE (NASDAQ:OXGN) shares rose in pre-market trading on Monday as it announced on the weekend that follow-up results from a phase two study of Zybrestat showed that patients with non-small cell lung cancer had better response and survival rates.

The controlled, randomized trial, called Falcon, tested Zybrestat in combination with three other treatments, compared to the control arm of the study.

More Read

TeleICU Lowers Mortality Rates and Length of Stay
Innovative Medical Devices Save Lives of Heart Patients But Often at a High Cost
Yes, “Too Big” Can be a Problem in Device & Diagnostics Companies, Too
The Future of Medical Education: Very Real Simulation of Procedures and Teamwork
Online Messaging Can Improve Support Group Relationships

An updated analysis, conducted roughly 11 months after enrollment of the last patient in June of last year, showed that the Zybrestat arm was well tolerated, with no significant cumulative toxicities. The partial response rate was 56% with Zybrestat, and 36% in the standard therapy arm.

In addition, a subgroup showed “meaningful improvements” in the average time to progression of the disease for patients with poor performance status, or sicker patients, OXiGENE said.

While the median time to progression for the overall patient population was similar in both arms of the study, those with poor performance status had a median time of 9.8 months in the Zybrestat arm, versus 3.8 months for the patients in the control group.

The company said that the suggestion that the Zybrestat combination could be especially beneficial in a sicker patient population should be explored in a larger trial.

“With several clinical trials completed in multiple indications, we now have a large body of data showing the excellent combinability potential of Zybrestat,” said CEO Peter Langecker.

“In addition, this study provides data in non-small cell lung cancer suggesting that Zybrestat may benefit patients with more advanced stages of disease.

“We believe that designing a development plan based on targeting this subgroup of patients could represent a sensible and achievable clinical strategy.”

Zybrestat is a small-molecule drug that targets and collapses tumour cells by depriving them of oxygen, and it is being tested in studies of patients with non-small cell lung cancer, thyroid cancer, ovarian cancer and other clinical trials.

The updated data was presented at the 2011 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois.–Deborah Sterescu

Source

 

TAGGED:lung cancermedical technology
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Do You Grind Your Teeth at Night? Here’s How Night Guards and TMJ Treatments Can Help
Do You Grind Your Teeth at Night? Here’s How Night Guards and TMJ Treatments Can Help
Dental health
May 21, 2025
The Secret To A Confident Smile: Top Tips For Better Teeth
The Secret To A Confident Smile: Top Tips For Better Teeth
Dental health
May 21, 2025
Clinical Expertise
Building Smarter Care Teams: Aligning Roles, Structure, and Clinical Expertise
Health care
May 18, 2025
Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
Health
May 15, 2025

You Might also Like

Siemens Varian partnership
BusinessNewsRadiologyTechnology

Siemens and Varian: Hooking Up to Mutual Advantage

June 13, 2013

Shifting Caseload and Markets in Tissue Ablation

September 6, 2011
Specimen Cup quality
HealthMedical InnovationsMedicare

Importance of Specimen Cup Quality for Medical Tests

January 5, 2024

Imagine: EMRs Without Big Brother

July 1, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?